Anupam Rama
Stock Analyst at JP Morgan
(3.72)
# 866
Out of 4,412 analysts
153
Total ratings
44.31%
Success rate
8.13%
Average return
Main Sectors:
Top Industries:
49 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DAWN Day One Biopharmaceuticals | Maintains: Overweight | $32 → $36 | $14.92 | +141.29% | 2 | Apr 22, 2024 | |
| CTMX CytomX Therapeutics | Upgrades: Neutral | n/a | $1.59 | - | 3 | Apr 22, 2024 | |
| ANAB AnaptysBio | Maintains: Neutral | $30 → $28 | $21.00 | +33.33% | 5 | Apr 1, 2024 | |
| ANNX Annexon | Maintains: Overweight | $11 → $13 | $4.70 | +176.60% | 3 | Apr 1, 2024 | |
| ORIC ORIC Pharmaceuticals | Maintains: Overweight | $19 → $18 | $8.07 | +123.05% | 2 | Mar 27, 2024 | |
| RAPT RAPT Therapeutics | Maintains: Neutral | $15 → $13 | $8.10 | +60.49% | 6 | Mar 27, 2024 | |
| SAGE Sage Therapeutics | Maintains: Overweight | $24 → $29 | $13.69 | +111.83% | 2 | Mar 26, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $31 → $34 | $21.06 | +61.44% | 5 | Mar 20, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $148 → $158 | $135.99 | +16.19% | 11 | Mar 20, 2024 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $35 → $45 | $24.88 | +80.87% | 5 | Mar 20, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $88 → $92 | $44.24 | +107.96% | 1 | Mar 18, 2024 | |
| FOLD Amicus Therapeutics | Maintains: Overweight | $21 → $19 | $10.28 | +84.82% | 4 | Mar 18, 2024 | |
| NUVL Nuvalent | Maintains: Overweight | $68 → $98 | $66.86 | +46.57% | 4 | Mar 6, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Overweight | $78 → $79 | $49.86 | +58.44% | 7 | Mar 6, 2024 | |
| SWTX SpringWorks Therapeutics | Maintains: Overweight | $73 → $74 | $45.53 | +62.53% | 3 | Mar 6, 2024 | |
| COGT Cogent Biosciences | Maintains: Overweight | $18 → $20 | $6.02 | +232.23% | 2 | Feb 27, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Overweight | $51 → $57 | $39.94 | +42.71% | 4 | Feb 23, 2024 | |
| ALVR AlloVir | Downgrades: Underweight | n/a | $0.80 | - | 2 | Dec 22, 2023 | |
| VERA Vera Therapeutics | Maintains: Overweight | $25 → $22 | $39.65 | -44.51% | 4 | Nov 30, 2023 | |
| ZLAB Zai Lab | Maintains: Overweight | $64 → $66 | $15.91 | +314.83% | 8 | Nov 30, 2023 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $211 → $115 | $128.77 | -10.69% | 8 | Oct 31, 2023 | |
| GTHX G1 Therapeutics | Downgrades: Underweight | n/a | $3.99 | - | 8 | Oct 6, 2023 | |
| OLMA Olema Pharmaceuticals | Maintains: Overweight | $16 → $19 | $9.95 | +90.95% | 2 | Sep 15, 2023 | |
| GBIO Generation Bio Co. | Maintains: Neutral | $8 → $9 | $2.90 | +210.34% | 2 | Aug 16, 2023 | |
| RLYB Rallybio | Maintains: Overweight | $17 → $18 | $1.70 | +958.82% | 2 | Aug 10, 2023 | |
| KOD Kodiak Sciences | Downgrades: Underweight | n/a | $3.28 | - | 6 | Jul 25, 2023 | |
| TVTX Travere Therapeutics | Initiates: Overweight | $26 | $5.26 | +394.30% | 1 | Jul 21, 2023 | |
| REPL Replimune Group | Maintains: Overweight | $38 → $50 | $6.42 | +678.82% | 2 | Jun 15, 2023 | |
| KNSA Kiniksa Pharmaceuticals | Maintains: Overweight | $19 → $20 | $17.88 | +11.86% | 1 | Mar 9, 2023 | |
| ELEV Elevation Oncology | Downgrades: Underweight | n/a | $3.62 | - | 2 | Nov 10, 2022 | |
| SLDB Solid Biosciences | Upgrades: Neutral | n/a | $8.98 | - | 2 | Sep 30, 2022 | |
| ATRA Atara Biotherapeutics | Downgrades: Neutral | $10 | $0.69 | +1,349.28% | 5 | Jul 13, 2022 | |
| PASG Passage Bio | Downgrades: Neutral | n/a | $1.32 | - | 3 | Mar 8, 2022 | |
| CYTK Cytokinetics | Initiates: Overweight | n/a | $65.34 | - | 1 | Dec 10, 2021 | |
| TBPH Theravance Biopharma | Upgrades: Neutral | n/a | $9.12 | - | 1 | Nov 5, 2021 | |
| VIR Vir Biotechnology | Upgrades: Neutral | n/a | $8.23 | - | 5 | Oct 25, 2021 | |
| PTGX Protagonist Therapeutics | Upgrades: Overweight | n/a | $25.15 | - | 2 | Oct 12, 2021 | |
| ERAS Erasca | Initiates: Overweight | n/a | $1.89 | - | 1 | Aug 10, 2021 | |
| AGIO Agios Pharmaceuticals | Downgrades: Neutral | n/a | $31.49 | - | 2 | Mar 1, 2021 | |
| DYN Dyne Therapeutics | Initiates: Overweight | n/a | $24.73 | - | 1 | Oct 12, 2020 | |
| ITOS iTeos Therapeutics | Initiates: Overweight | n/a | $10.80 | - | 1 | Aug 18, 2020 | |
| ALNY Alnylam Pharmaceuticals | Downgrades: Neutral | n/a | $143.31 | - | 2 | May 7, 2020 | |
| YMAB Y-mAbs Therapeutics | Initiates: Overweight | n/a | $14.71 | - | 1 | Dec 24, 2019 | |
| DVAX Dynavax Technologies | Upgrades: Overweight | n/a | $11.21 | - | 2 | May 10, 2018 | |
| CLSD Clearside Biomedical | Maintains: Overweight | n/a | $1.34 | - | 2 | Mar 6, 2018 | |
| IFRX InflaRx | Initiates: Overweight | n/a | $1.33 | - | 1 | Dec 4, 2017 | |
| PTCT PTC Therapeutics | Upgrades: Neutral | n/a | $28.57 | - | 2 | Nov 16, 2017 | |
| IRWD Ironwood Pharmaceuticals | Downgrades: Neutral | n/a | $7.82 | - | 1 | Jul 21, 2017 | |
| ARRY Array Technologies | Upgrades: Overweight | n/a | $12.40 | - | 1 | May 3, 2017 |
Day One Biopharmaceuticals
Apr 22, 2024
Maintains: Overweight
Price Target: $32 → $36
Current: $14.92
Upside: +141.29%
CytomX Therapeutics
Apr 22, 2024
Upgrades: Neutral
Price Target: n/a
Current: $1.59
Upside: -
AnaptysBio
Apr 1, 2024
Maintains: Neutral
Price Target: $30 → $28
Current: $21.00
Upside: +33.33%
Annexon
Apr 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $4.70
Upside: +176.60%
ORIC Pharmaceuticals
Mar 27, 2024
Maintains: Overweight
Price Target: $19 → $18
Current: $8.07
Upside: +123.05%
RAPT Therapeutics
Mar 27, 2024
Maintains: Neutral
Price Target: $15 → $13
Current: $8.10
Upside: +60.49%
Sage Therapeutics
Mar 26, 2024
Maintains: Overweight
Price Target: $24 → $29
Current: $13.69
Upside: +111.83%
Syndax Pharmaceuticals
Mar 20, 2024
Maintains: Overweight
Price Target: $31 → $34
Current: $21.06
Upside: +61.44%
Neurocrine Biosciences
Mar 20, 2024
Maintains: Overweight
Price Target: $148 → $158
Current: $135.99
Upside: +16.19%
BridgeBio Pharma
Mar 20, 2024
Maintains: Overweight
Price Target: $35 → $45
Current: $24.88
Upside: +80.87%
Ultragenyx Pharmaceutical
Mar 18, 2024
Maintains: Overweight
Price Target: $88 → $92
Current: $44.24
Upside: +107.96%
Amicus Therapeutics
Mar 18, 2024
Maintains: Overweight
Price Target: $21 → $19
Current: $10.28
Upside: +84.82%
Nuvalent
Mar 6, 2024
Maintains: Overweight
Price Target: $68 → $98
Current: $66.86
Upside: +46.57%
Apellis Pharmaceuticals
Mar 6, 2024
Maintains: Overweight
Price Target: $78 → $79
Current: $49.86
Upside: +58.44%
SpringWorks Therapeutics
Mar 6, 2024
Maintains: Overweight
Price Target: $73 → $74
Current: $45.53
Upside: +62.53%
Cogent Biosciences
Feb 27, 2024
Maintains: Overweight
Price Target: $18 → $20
Current: $6.02
Upside: +232.23%
IDEAYA Biosciences
Feb 23, 2024
Maintains: Overweight
Price Target: $51 → $57
Current: $39.94
Upside: +42.71%
AlloVir
Dec 22, 2023
Downgrades: Underweight
Price Target: n/a
Current: $0.80
Upside: -
Vera Therapeutics
Nov 30, 2023
Maintains: Overweight
Price Target: $25 → $22
Current: $39.65
Upside: -44.51%
Zai Lab
Nov 30, 2023
Maintains: Overweight
Price Target: $64 → $66
Current: $15.91
Upside: +314.83%
Sarepta Therapeutics
Oct 31, 2023
Maintains: Overweight
Price Target: $211 → $115
Current: $128.77
Upside: -10.69%
G1 Therapeutics
Oct 6, 2023
Downgrades: Underweight
Price Target: n/a
Current: $3.99
Upside: -
Olema Pharmaceuticals
Sep 15, 2023
Maintains: Overweight
Price Target: $16 → $19
Current: $9.95
Upside: +90.95%
Generation Bio Co.
Aug 16, 2023
Maintains: Neutral
Price Target: $8 → $9
Current: $2.90
Upside: +210.34%
Rallybio
Aug 10, 2023
Maintains: Overweight
Price Target: $17 → $18
Current: $1.70
Upside: +958.82%
Kodiak Sciences
Jul 25, 2023
Downgrades: Underweight
Price Target: n/a
Current: $3.28
Upside: -
Travere Therapeutics
Jul 21, 2023
Initiates: Overweight
Price Target: $26
Current: $5.26
Upside: +394.30%
Replimune Group
Jun 15, 2023
Maintains: Overweight
Price Target: $38 → $50
Current: $6.42
Upside: +678.82%
Kiniksa Pharmaceuticals
Mar 9, 2023
Maintains: Overweight
Price Target: $19 → $20
Current: $17.88
Upside: +11.86%
Elevation Oncology
Nov 10, 2022
Downgrades: Underweight
Price Target: n/a
Current: $3.62
Upside: -
Solid Biosciences
Sep 30, 2022
Upgrades: Neutral
Price Target: n/a
Current: $8.98
Upside: -
Atara Biotherapeutics
Jul 13, 2022
Downgrades: Neutral
Price Target: $10
Current: $0.69
Upside: +1,349.28%
Passage Bio
Mar 8, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.32
Upside: -
Cytokinetics
Dec 10, 2021
Initiates: Overweight
Price Target: n/a
Current: $65.34
Upside: -
Theravance Biopharma
Nov 5, 2021
Upgrades: Neutral
Price Target: n/a
Current: $9.12
Upside: -
Vir Biotechnology
Oct 25, 2021
Upgrades: Neutral
Price Target: n/a
Current: $8.23
Upside: -
Protagonist Therapeutics
Oct 12, 2021
Upgrades: Overweight
Price Target: n/a
Current: $25.15
Upside: -
Erasca
Aug 10, 2021
Initiates: Overweight
Price Target: n/a
Current: $1.89
Upside: -
Agios Pharmaceuticals
Mar 1, 2021
Downgrades: Neutral
Price Target: n/a
Current: $31.49
Upside: -
Dyne Therapeutics
Oct 12, 2020
Initiates: Overweight
Price Target: n/a
Current: $24.73
Upside: -
iTeos Therapeutics
Aug 18, 2020
Initiates: Overweight
Price Target: n/a
Current: $10.80
Upside: -
Alnylam Pharmaceuticals
May 7, 2020
Downgrades: Neutral
Price Target: n/a
Current: $143.31
Upside: -
Y-mAbs Therapeutics
Dec 24, 2019
Initiates: Overweight
Price Target: n/a
Current: $14.71
Upside: -
Dynavax Technologies
May 10, 2018
Upgrades: Overweight
Price Target: n/a
Current: $11.21
Upside: -
Clearside Biomedical
Mar 6, 2018
Maintains: Overweight
Price Target: n/a
Current: $1.34
Upside: -
InflaRx
Dec 4, 2017
Initiates: Overweight
Price Target: n/a
Current: $1.33
Upside: -
PTC Therapeutics
Nov 16, 2017
Upgrades: Neutral
Price Target: n/a
Current: $28.57
Upside: -
Ironwood Pharmaceuticals
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $7.82
Upside: -
Array Technologies
May 3, 2017
Upgrades: Overweight
Price Target: n/a
Current: $12.40
Upside: -